A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks. Approximately 800 additional participants will be enrolled in the 12-month Addendum 7 to assess safety of a different titration regimen.
Inclusion Criteria:
Treatment Extension: (Study Period II Placebo Group Only)
Exclusion Criteria:
Addendum 7 Exclusion Criteria:
Homewood, Alabama 35209, United States
Elk Grove Village, Illinois 60007, United States
Mendota Heights, Minnesota 55120, United States
Shinjuku-ku, 160-0008, Japan
Suita-shi, 565-0853, Japan